Phosphoproteomics Study Based on In Vivo Inhibition Reveals Sites of Calmodulin–Dependent Protein Kinase II Regulation in the Heart
Arjen Scholten, Christian Preisinger, Eleonora Corradini, Vincent J. Bourgonje, Marco L. Hennrich, Toon A. B. van Veen, Paari D. Swaminathan, Mei-Ling Joiner, Marc A. Vos, Mark E. Anderson and Albert J. R. Heck

J Am Heart Assoc. 2013;2:e000318; originally published August 7, 2013;
doi: 10.1161/JAHA.113.000318
The Journal of the American Heart Association is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/2/4/e000318

Data Supplement (unedited) at:
http://jaha.ahajournals.org/content/suppl/2013/08/08/jah3274.DC1.html

Subscriptions, Permissions, and Reprints: The Journal of the American Heart Association is an online only Open Access publication. Visit the Journal at http://jaha.ahajournals.org for more information.
Phosphoproteomics Study Based on In Vivo Inhibition Reveals Sites of Calmodulin-Dependent Protein Kinase II Regulation in the Heart

Arjen Scholten, PhD,* Christian Preisinger, PhD,* Eleonora Corradini, MSc; Vincent J. Bourgonje, PhD; Marco L. Hennrich, PhD; Toon A. B. van Veen, PhD; Paari D. Swaminathan, MBBS; Mei-Ling Joiner, PhD; Marc A. Vos, PhD; Mark E. Anderson, MD, PhD; Albert J. R. Heck, PhD

Background—The multifunctional Ca2+- and calmodulin-dependent protein kinase II (CaMKII) is a crucial mediator of cardiac physiology and pathology. Increased expression and activation of CaMKII has been linked to elevated risk for arrhythmic events and is a hallmark of human heart failure. A useful approach to determining CaMKII’s role therein is large-scale analysis of phosphorylation events by mass spectrometry. However, current large-scale phosphoproteomics approaches have proved inadequate for high-fidelity identification of kinase-specific roles. The purpose of this study was to develop a phosphoproteomics approach to specifically identify CaMKII’s downstream effects in cardiac tissue.

Methods and Results—To identify putative downstream CaMKII targets in cardiac tissue, animals with myocardial-delimited expression of the specific peptide inhibitor of CaMKII (AC3-I) or an inactive control (AC3-C) were compared using quantitative phosphoproteomics. The hearts were isolated after isoproterenol injection to induce CaMKII activation downstream of β-adrenergic receptor agonist stimulation. Enriched phosphopeptides from AC3-I and AC3-C mice were differentially quantified using stable isotope dimethyl labeling, strong cation exchange chromatography and high-resolution LC-MS/MS. Phosphorylation levels of several hundred sites could be profiled, including 39 phosphoproteins noticeably affected by AC3-I-mediated CaMKII inhibition.

Conclusions—Our data set included known CaMKII substrates, as well as several new candidate proteins involved in functions not previously implicated in CaMKII signaling. (J Am Heart Assoc. 2013;2:e000318 doi: 10.1161/JAHA.113.000318)

Key Words: CaMKII • mass spectrometry • phosphorylation • proteomics • transgenic mouse model

A beating heart relies on the concerted action of many intertwined signaling networks that regulate cardiac contraction and relaxation at the molecular level. In cardiac myocytes (CMs) 1 of the best characterized signaling events is the β-adrenergic receptor pathway, which directly regulates intracellular Ca2+ concentrations. First Ca2+ enters the CM through L-type calcium channels (LTCCs), which triggers release of Ca2+ from intracellular stores in the sarcoplasmic reticulum (SR) via the ryanodine receptor (Ryr). Reuptake of Ca2+ via sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) is regulated by phospholamban, and this, with outward transport via the sodium/calcium exchanger (NCX), completes the Ca2+ cycle of the beating heart.1 The Ca2+ cycle is tunable by circulating β-adrenergic receptor agonists such as epinephrine and norepinephrine to accommodate requested changes in cardiac performance.

The second-messenger molecule cAMP and cAMP-dependent protein kinase (PKA) form the first intracellular response, which directly affects the adjustability of adrenergically driven intracellular Ca2+ levels (reviewed by references 1,2). A handful of cardiac PKA phosphorylation targets mediating this response have been identified. More recently, another kinase revealed itself as a key player in the adrenergic response: the
multifunctional Ca\textsuperscript{2+} and calmodulin-dependent protein kinase II\textsuperscript{3} (CaMKII). CaMKII is activated at elevated intracellular Ca\textsuperscript{2+} levels. Ca\textsuperscript{2+} binds calmodulin (CaM), and calcified CaM binds to the CaMKII regulatory domain.\textsuperscript{4} Both PKA and CaMKII are among the most abundant kinases in heart.\textsuperscript{5} There are 4 distinct CaMKII genes (\textit{x}-\textit{\textalpha}) that encode multiple enzyme splice variants. CaMKII\textit{x} and CaMKII\textit{\textalpha} are present in heart, and excessive CaMKII\textit{\textalpha} activity is most implicated in myocardial disease.\textsuperscript{6,7} However, all CaMKII isoforms share highly conserved catalytic and regulatory domains and compete for overlapping substrates.

An adrenergically driven increase in CaMKII activity leads to direct phosphorylation of phospholamban (PLN) and the type II ryanodine receptor (Ryr2), at Thr17 and Ser2815, respectively, thereby directly affecting the Ca\textsuperscript{2+} cycle.\textsuperscript{8,9} These events, together with CaMKII autophosphorylation at Thr287,\textsuperscript{10} are considered hallmarks of cardiac CaMKII activity. Intriguingly, both these events are intertwined with cAMP action, as PLN and Ryr2 are also phosphorylated by PKA at nearby sites Ser16\textsuperscript{11} and Ser2809,\textsuperscript{12} respectively. In addition, other cAMP pathways acting through exchange proteins activated by cAMP, which are PKA independent, have also been reported.\textsuperscript{13} Ca\textsuperscript{2+}/CaM-independent CaMKII activation also occurs via oxidation of a pair of regulatory domain methionines (Met281/282).\textsuperscript{14}

Heart failure is characterized by activation of the sympathetic nervous system and subsequent overstimulation of cardiac \beta-adrenergic signaling. As a consequence, CaMKII expression\textsuperscript{15} and activity\textsuperscript{16} were found to be increased in human heart failure. Mouse models with cardiac overexpression of CaMKII\textit{x} serve as a model for heart failure,\textsuperscript{17} whereas mice with myocardial CaMKII inhibition by transgenic expression of an inhibitory peptide\textsuperscript{18} or gene deletion (CaMKII\textit{\textalpha}\textsuperscript{7-7})\textsuperscript{2} are protected from various pathological stimuli leading to heart failure, including isoproterenol toxicity.\textsuperscript{19} In contrast, CaMKII activity is increased in compensated hypertrophy and arrhythmia, whereas CaMKII expression remains at basal levels.\textsuperscript{20} These findings support a view that CaMKII is a critical pathological signal transducer in myocardium for mediating the effects of chronic \beta-adrenergic stimulation.

CaMKII signaling is heavily intertwined with other cardiac signaling events; therefore, understanding cardiac CaMKII signaling in more depth would benefit from a systems-wide method such as large-scale phosphoproteomics. Although such methodology can reveal tens of thousands of phosphorylation sites,\textsuperscript{21-23} pinpointing the responsible kinase for each detected site is cumbersome because consensus sequences are often promiscuous. Ideally, a targeted phosphoproteomics approach, which only reveals phosphorylation sites affected by a single kinase, in this case CaMKII, is more appropriate. Here we present such a highly specific methodology to probe in vivo cardiac phosphorylation events, utilizing AC3-I transgenic mice, a highly validated model of myocardial-selective CaMKII inhibition.\textsuperscript{18} As a control, we used transgenic mice from the same genetic background expressing AC3-C, a scrambled and inactive form of AC3-I (Figure 1). This novel approach led to the identification of a defined subset of direct and indirect cardiac CaMKII targets. These novel proteins were found in various cellular compartments not previously associated with CaMKII activity, such as proteins within the z-disc and a set of distinct sarcomeric proteins. Therefore, this study reveals interesting and novel roles for CaMKII in health and disease.

**Materials and Methods**

**Animals and Treatment Regime**

All animal experiments were performed according to the ethical guidelines defined by the University of Iowa and the University Medical Centre Utrecht. All mice were bred in a C57BL/6 background. For proteomics, 2 AC3-I and 2 AC3-C mice were treated with a single bolus injection of 15 mg/kg isoproterenol (CAS# 5984-95-2; Sigma) for 30 minutes. Also 2 mice each with either transgenic peptide were treated with vehicle. The animals were euthanized, and their hearts isolated, flushed with ice-cold PBS, and immediately snap-frozen in liquid nitrogen, before storage at \(-80°C\). For Western blots, mice were treated identically.

**Tissue Lysis, Sample Preparation, and Western Blotting**

Whole hearts were taken from the \(-80°C\) storage and further frozen in liquid nitrogen and subsequently pulverized in a
custom-made chilled steel mortar. For Western blotting, tissue was further lysed with RIPA lysis buffer (20 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 10 mmol/L Na₂HPO₄, 1% [v/v] Triton X-100, 1% [w/v] Na-deoxycholate, 0.1% [w/v] SDS, 1 mmol/L EDTA, 50 mmol/mL NaF, 2 mmol/L PMSF, and 14 μg/mL aprotinin). Isolated protein samples were loaded on SDS-PAGE for subsequent Western blotting. For detection, chemiluminescence was performed using an ECL-kit from Amersham. The following antibodies were used: anti-phospho-Cacnb2 antibodies made by Yenzyme, anti-Cacnb2 (Thr549; Neuromab), anti-phosphorylated-CaMKII (Thr 287; Upstate), anti-phospholamban (Upstate), and anti-phospho-PLN (Thr17; Santacruz).

**Strong Cation Exchange and LC-MS/MS Analysis**

Whole hearts were taken from the −80°C storage, pulverized as above, and taken up in 500 μL of lysis buffer (10 mmol/L sodium phosphate buffer [pH 7.8], 150 mmol/L NaCl, 8 mol/L urea, 1× PhosStop tablet, and complete mini protease inhibitors [both Roche Diagnostics]) and left at room temperature for 10 minutes. Samples were sonicated 3 times on ice for 1 minute with 2 minutes of resting on ice and centrifuged at 20 000g for 15 minutes at 4°C. This procedure was repeated once, and the supernatants were combined. Protein concentrations were measured using a Bradford assay (BioRad). The individual samples were reduced with 10 mmol/L dithiothreitol for 30 minutes at 56°C and alkylated by the addition of 55 mmol/L iodoacetamide and incubation for 45 minutes at room temperature in the dark. Lysates were digested with Lys C (ratio 1:100 w/v) and alkylated cysteines as static modifications. Samples were dried under vacuo, and 20 μL of 1% ammonium bicarbonate was added to a final concentration of 2 mol/L urea. Trypsin (ratio 1:100 w/v) was added, and the samples were digested overnight at 37°C. Proteolytically cleaved samples were desalted and dimethylated on a Sep-Pak according to Hennrich et al.25 A total of 40 fractions were collected. Each mouse set was analyzed in duplicate (technical replicates) by LC-MS/MS as described below. The fractions enriched in phosphorylated peptides (11 fractions 7 to 17) were analyzed in quadruplicate Hennrich twice using CID as fragmentation method and twice with HCD. Nanoflow LC-MS/MS was performed by coupling an Agilent 1100 HPLC system (Agilent Technologies, Waldbronn, Germany) to a LTO-Orbitrap Velos mass spectrometer (Thermo Electron, Bremen, Germany) as described previously.26 The phosphorylated fractions were run with a 2-hour gradient, whereas the other fractions were analyzed using a 3-hour gradient elution. The early SCX fractions containing the phosphorylated peptides were run twice, once using fragmentation by CID in the ion trap and once using HCD fragmentation with fragment analysis in the Orbitrap.

**Data Analysis**

All raw data files of the individual SCX fractions of each of the 2 mouse experiments were imported into Proteome Discoverer v1.3.0.339 Hennrich and the combined peak list was split into CID and HCD data (where applicable) before database searching. Subsequently, CID and HCD peak lists were searched individually against an International Protein Index (IPI; http://www.ebi.ac.uk/​ipi) database containing mouse sequences and common contaminants such as bovine serum albumin and human keratins (IPI-Mouse v3.84; 60 248 sequences) through a direct connection to our in-house Mascot server (Mascot v2.3.2.1, Matrix Science, London, UK). The following settings were used: carbamidomethylation on cysteines as static modification; light, intermediate, and heavy dimethylation of peptide N-termini and lysine side chains, as well as oxidation on methionine and phosphorylation on serine, threonine, or tyrosine as variable modifications; and precursor mass tolerance of 20 ppm and 0.8 Da on the fragment masses (for CID) but 20 ppm and 0.02 Da for HCD searching. The enzyme was specified as trypsin, and 2 missed cleavages were allowed. For both identification and quantitation, only spectra within the score limits of the 1% false discovery rate (FDR) were accepted, based on Mascot score thresholds. These were calculated independently for CID and HCD data in each data set using the built-in FDR calculator of Proteome Discoverer, which is based on Mascot’s built-in FDR calculation. The event detector and precursor ion quantifier algorithms of Proteome Discoverer were used for quantitation using 2-ppm mass variability and 0.2-minute retention time tolerance on precursor ion pairs. Quantitation is based on the ratio of the summed areas of 3 matched isotope patterns (a feature) across the eluting chromatographic peak of that feature. The peptide ratios are calculated using the same number of isotopes. Protein ratios are based on the median peptide ratio, with exclusion of the identified phosphopeptides. At least 2 isotopic peaks were required for inclusion, as well as a minimal signal-to-noise level of 3. Protein identifications over all 4 analyses were combined and grouped by Proteome Discoverer. Each peptide spectral match (PSM) Mascot peptide score >25) of a phosphorylated peptide was isolated from the data in Proteome Discoverer. Site localization was performed using the pRS algorithm.27 Probability
scores >75% were considered localized. Phospho-PSMs were then grouped according to their sequence and site(s) of phosphorylation. If multiple quantitative data points for a unique phosphopeptide (including proper site localization) were available, these were averaged, and the standard deviation was calculated. All raw and annotated data are freely available through ProteomeXchange (http://www.proteomexchange.org) under accession number PXD000174 and ProteomeXchange submission title CaMKII Cardiac Phosphoproteome. Icelogs were generated using the Icelogo software package. All Icelogs were generated with a cutoff \( P<0.01 \).

**Immunohistochemistry**

Frozen heart tissue from an AC3-I mouse was serially sectioned in 10-μm slices that were collected on aminopropyltriethoxysilane-coated glass slides. Immunohistochemistry was performed as described previously. Primary antibodies against Carp3 (Rabbit, Crp3 H-46 sc-98827, 1:100; SantaCruz) were used. Secondary labeling was performed with appropriate Alexa Fluor 594 (1:250) conjugated with whole IgG antibodies (Jackson Laboratories).

**Results**

To establish the downstream phosphorylation targets affected by CaMKII inhibition in vivo in cardiac tissue, the phosphorylation states of mice with transgenic expression of either AC3-I or AC3-C (Figure 1A) were compared using quantitative proteomics. We used SCX-based phosphopeptide enrichment, dimethyl stable isotope labeling, and high-resolution LC-MS/MS analysis (Figure 1B). AC3-I is a potent, highly specific peptide inhibitor of CaMKII, whereas AC3-C is a scrambled nonfunctional homolog peptide (Figure 1A). The AC3-I peptide mimics the autoinhibitory sequence of CaMKII (mouse Q6PHZ2, amino acids 283 to 292) by posing as a pseudosubstrate with an intact docking site (Arg284), but a deficient phosphoacceptor (Thr287 substituted by an alanine; Figure 1A). Cardiomyocyte-specific expression of AC3-I leads to potent inhibition of CaMKII in vivo as demonstrated previously. cDNA constructs of AC3-I and AC3-C fused to GFP were expressed under control of the cardiac-specific myh6 promoter. This excludes any distant effects by inhibition of CaMKII in other organs or in nonmyocardial cardiac cells that may modulate cardiac performance. Chronic expression of AC3-I has no structural myocardial phenotype, as these mice age and function normally and have equal expression of CaMKII, but show reduced chronotropic activation and preserved myocardial function after an isoproterenol challenge. To investigate this in more detail, we evaluated the differences in protein expression between both mouse models. Little variation was observed between AC3-I and AC3-C mouse hearts, as indicated from the 1410 quantified proteins, of which 1329 (>94%) presented a <2-fold difference between AC3-I and AC3-C (Figure 1C, Table S1), 90% of which were within 1.5-fold.

To identify downstream phosphorylation targets of CaMKII in the heart, the phosphoproteome of 2 AC3-I and 2 AC3-C mice were quantitatively compared after an intraperitoneal injection of isoproterenol (see Materials and Methods for details; Figure 1B). Prior to extensive LC-MS/MS analysis, we checked the phosphorylation of 2 known CaMKII target sites after identical isoproterenol treatment as described above: Thr17 of cardiac phospholamban (PLN) and Thr287 auto-phosphorylation of CaMKII (Figure 2A). Normalization to protein levels of PLN indicates that both phosphorylations were increased in the AC3-C mice. As expected, the response was blunted in the AC3-I mice. Similar trends were observed at the established Thr549 site of the β-subunit of the voltage-gated calcium channel (Cacnb2) (Figure 2B).

Subsequently, we enriched for cardiac phosphopeptides from the labeled mixture of AC3-C and AC3-I peptides. This led to the identification of 525 unique phosphopeptides on 282 phosphoproteins. Finally, using stringent filtering and the pRS phosphorylation site localization algorithm, 310 confidently localized phosphorylation sites could be quantified (Table S2). Evaluation of their phosphorylation motif using Icelogo showed a mixture of kinase motifs, including CaMKII’s general motif RXX[pS/pT], but also the SP-directed motif and acidic-directed motifs (Figure 2C). We then isolated the putative CaMKII sites (84 in total) by selecting the motifs with an arginine or lysine residue on position −3 while disregarding those that contained a proline at position +1 ([R/K]XX[pS/pT] [noP]) and made an additional motif (Figure 2D).

Quantitative analysis of the phosphorylated peptides revealed 36 sites that were downregulated on AC3-I expression, indicative of a direct inhibitory effect of AC3-I on these particular phosphorylation sites. In contrast, another 15 sites showed a negative AC3-I/AC3-C ratio, meaning that phosphorylation at these sites was increased when CaMKII was inhibited, presumably an indirect effect of myocardial CaMKII inhibition. Satisfactorily, an Icelogo of the downregulated sites showed clear enrichment of RXXpS-based phosphosites (Figure 2E).

To further structure our quantitative phosphorylation data, we cross-referenced published reports to verify the function of each regulated phosphoprotein in our screen (Figure 3). This showed several expected functional entities, such as ion handling, gene expression, and cytoskeletal proteins involved in contractility. We also found targets related to microtubule formation and upkeep that were not previously recognized as being affected by CaMKII. As expected, we identified other signaling proteins affected by CaMKII inhibition, including the myosin light chain kinase (Ser1798 and Ser1801.
This is an interesting finding, as it suggests a direct connection between CaMKII inhibition and contractility.

**Discussion**

**CaMKII in Health and Disease**

Healthy CaMKII has thus far been implicated in 3 major physiological cardiac functions, that is, excitation-contraction coupling (ECC), excitation-transcription coupling (ETC), and “fight-or-flight” heart rate increases. As part of the ongoing efforts to understand CaMKII’s function, research has mainly focused on 3 molecular nodes: (1) the regulation of ion channels (Ca^{2+}, Na^+, and K^+ channels), (2) the regulation of SR-Ca^{2+} via the ryanodine receptor and the SERCA/PLN complex, and (3) HDAC5/NFAT/MEF2-mediated transcription.\(^34\) Over the past 2 decades an enormous body of work has also revealed that CaMKII is a potential driver of myocardial hypertrophy, arrhythmia, and heart failure. Both its activity and expression are increased in patients and animal models of these cardiac diseases.\(^{15,20}\) Also, inhibition of cardiac CaMKII in various ways protects the heart against its damaging effects (reviewed in Anderson et al.\(^{35}\)). In pathological hypertrophy, patients suffer from defective ECC and ETC, leading to apoptosis and arrhythmias. However, the connection between CaMKII activity and expression and heart disease is not well understood. We reasoned that an important first step toward understanding the molecular pathways affected by CaMKII was to measure direct and indirect CaMKII target phosphorylation sites after isoproterenol stimulation.

**Methodology to Probe CaMKII Action Directly in the Myocardium**

Monitoring molecular pathways affected by CaMKII are not trivial because the field suffers from lack of a suitable,
Cardiac Phosphorylation Targets of CaMKII

Scholten et al.

Signaling protein complexes, which may disintegrate on downregulated (red and pink) sites categorized by specific protein 1; Naca, nascent polypeptide-associated complex subunit isoform 3 of Arf-GAP domain and FG repeats-containing protein 1; isoform 1 of uncharacterized protein KIAA0564 homologue; Agfg1, cardiac phospholamban; Ahnak, AHNAK nucleoprotein isoform 1; IGFN, immunoglobulin-like and lin-dependent protein kinase II; Synpo2, synaptopodin-2; Lmod2, gene names are used. For specific protein 3; IGFN, immunoglobulin-like and lin-dependent protein kinase II; Synpo2, synaptopodin-2; Lmod2, contractile cardiac myocytes. Therefore, such studies are ideally performed directly in cardiac tissue. Although KN-93 is used throughout the literature, its specificity for CaMKII is still debated, and systemic administration may induce peripheral effects by inhibition of CaMKII at other sites in the body. In a more focused approach, one could use the established CaMKII-null mouse and compare its phosphoryproteome after isoproterenol stimulus with wild-type littermates using quantitative phosphoantibodies. Potential drawback of such an approach is that the CaMKII-null phenotype is likely compensated through significant changes in cardiac protein expression. In addition, it is foreseen that, like PKA, CaMKII engages in higher-order signaling protein complexes, which may disintegrate on the absence of CaMKII, and cause signaling deviation far beyond CaMKII action alone. Therefore, it is preferential to use a more subtle transgenic model that expresses a cardiac-specific kinase-dead version of CaMKII or a specific (peptide) inhibitor of CaMKII. The former has not been described, but for the latter 2 models are available: one based on the transgenic expression of the SR-targeted AIP,38 the other on a general CaMKII inhibitory sequence derived from CaMKII’s own autoinhibitory domain, called AC3-I.18,31 Here, we probed the effect of AC3-I-mediated CaMKII inhibition on cardiac protein phosphorylation after a short β-adrenergic stimulation (30 minutes of isoproterenol). As AC3-I mice have no apparent phenotype when not challenged into hypertrophy, we consider the observed changes as the functional outcome of healthy CaMKII action.

Established Targets of CaMKII

Only a handful direct phosphorylation targets of CaMKII are documented in the heart, with PLN-Thr17 being the best validated. Phosphorylation of PLN leads to aberration of its inhibitory function on SERCA2 and hence an increase in Ca2+ reuptake by the SR. As expected, transgenically expressed AC3-I negatively affects phosphorylation at this site, as shown previously, and also in our screen (Figure 2B), thereby validating our approach. In addition, we found several of the known, or predicted, protein targets of cardiac CaMKII in our screen. In addition to Thr549 (Figure 2A), on Cacnb2 we identified a novel site at Ser156 (3.3-fold upregulated) that did not conform to the CaMKII motif, indicative of negative regulation at this site. Among the proteins involved in expression and translation (Figure 3) was Eif4B (eukaryotic translation initiation factor 4B), a ribosomal RNA helicase. In vitro phosphorylation screens identified Eif4B as a CaMKII substrate, although the site was lacking.39 Using our approach, 2 phosphorylation hot spots were detected on this protein (Figure 4), one containing Ser418, 420, 422, and 425 (Table S2) and another containing Ser495, 497, and 498. The former is functionally described as regulated at Ser422 by several kinases, including S6-kinase1 and Akt, and we did not find these sites regulated (Table S2). The latter hot spot was represented by 4 different phosphopeptides, all of which were found to be downregulated between 3- to 5-fold in AC3-I mice. In addition, Ser497 is a putative CaMKII site with an unknown function. Therefore, it is preferential to use a more subtle transgenic model that expresses a cardiac-specific kinase-dead version of CaMKII or a specific (peptide) inhibitor of CaMKII. The former has not been described, but for the latter 2 models are available: one based on the transgenic expression of the SR-targeted AIP, the other on a general CaMKII inhibitory sequence derived from CaMKII’s own autoinhibitory domain, called AC3-I. Here, we probed the effect of AC3-I-mediated CaMKII inhibition on cardiac protein phosphorylation after a short β-adrenergic stimulation (30 minutes of isoproterenol). As AC3-I mice have no apparent phenotype when not challenged into hypertrophy, we consider the observed changes as the functional outcome of healthy CaMKII action.

Figure 3. Phosphorylation sites affected by AC3-I-mediated CaMKII inhibition in mouse heart. Depicted are all upregulated (green) and downregulated (red and pink) sites categorized by specific function. Gene names are used. For specific ratios observed, see Table S2. *Means the mentioned site contains the minimum CaMKII motif (RXpS/pT). Boxed proteins or sites are verified CaMKII targets. For acronyms, see Table S2. CaMKII indicates calcium- and calmodulin-dependent protein kinase II; Synpo2, synaptotogin-2; Lmod2, leiomodin-2; Capzb, capping protein subunit beta; Palld, Palladin; Cobi1, Cordon-bleu protein-like 1; Csrp3, cysteine- and glycine-rich protein 3; IGFN, immunoglobulin-like and fibrinectin type III domain-containing protein 1; Myh, myosin heavy chain; Myl, myosin light chain; Mi22, histone-lysine N-methyltransferase ML2; Eif, eukaryotic translation initiation factor; Clasp1, CLIP-associating protein 1 isofrom 2; Slafl, isoform 1 of SLAIN motif-containing protein 2; Mapt, microtubule-associated protein tau; Speg, isoform 1 of striated muscle-specific serine/threonine-protein kinase; Pin, cardiac phospholamban; Ahnak, AHNAK nucleoprotein isoform 1; Mypt2, myosin phosphatase; Plin, isoform 1 of Perilipin-1; Kioa564, isoform 1 of uncharacterized protein KIAA0564 homologue; Agfg1, isoform 3 of Arf-GAP domain and FG repeats-containing protein 1; Arfgap1, isoform 1 of ADP-ribosylation factor GTPase-activating protein 1; Naca, nascent polypeptide-associated complex subunit alpha.

DOI: 10.1161/JAHA.113.000318

Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at Universiteitsbibliotheek Utrecht on February 5, 2014
CaMKII Regulates Phosphorylation of Many Myofibril Proteins in the z-Disc and a-Band

AC3-I regulated sites categorized in different cellular compartments and physiological functions (Figure 3). In our phosphoproteomics screen, the sarcomere category contained the most regulated sites. Even though our analysis is somewhat biased toward the more abundant myofilament proteins, many detailed observations could be made in this compartment, of which several are described below.

Scrutinizing the literature we could annotate the exact intracellular localization of each observed phosphoprotein. A set of z-disc proteins, a-band proteins, but also costamere proteins was observed (Figure 5, Table S2). The sarcomere of cardiac muscle is strictly organized in thick filaments that contain myosin and thin filaments consisting of filamentous actin. The thin filaments align and cross-link via α-actinin dimers at the z-disc and form a bridge to the thick filaments in the a-band (reviewed in Clark et al; Figure 5A). The cardiac z-disc is an intricate network of many contractile (regulatory) proteins. Costameric proteins link the z-disc with the sarcolemma to transmit force between these 2 regions.

When grouping the phosphoproteins by confirmed intracellular localization and known binding partners, a site-specific pattern became visible. Although the costameric proteins were found to be phosphorylated, none of them seemed affected by isoproterenol in AC3-I mice, whereas both the z-disc and a-band proteins were (Figure 5A). This suggests that isoproterenol-sensitive CaMKII is present or at least influences signaling nodes, specifically at these defined locations in the heart.

Titin is a major stability component of the cardiac sarcomere with its N-terminus embedded in the z-disc and its C-terminus extending into the a-band. We observed 5 different phosphopeptides on titin, harboring in total 7 quantified phosphorylation sites (Table S2). One site, Ser5070 at the z-disc part of titin, is a putative CaMKII site (RXXpS) only present in isoform 3 (A2ASS6-3), which was downregulated almost 20-fold in AC3-I mice. At the same time, at the C-terminal end, we found 2 adjacent phosphorylation sites Thr34450 (in isoform 1, A2ASS6-1) and Ser34451, of which the former was found to be 2.6-fold upregulated and the latter unchanged. These observations caused us to speculate that CaMKII directly influences the phosphorylation state of titin and thereby likely regulates sarcomere action. Further research should reveal more detailed information on the exact nature of these specific events.

We found Csrp3 (cysteine and glycine-rich protein 3, or Crp3, also called muscle lim protein) less phosphorylated in...
AC3-I murine hearts at Thr84 and Ser95 (both \(>2.5\)-fold) than in AC3-C hearts. Csrp3 is crucial to the development and maintenance of cardiac cytoarchitectural organization. Mice deficient in this protein develop severe dilated cardiomyopathy within several weeks after birth.\(^4\)\(^5\) Csrp3 localizes to the z-disc, where it binds telethonin (Tcap, phosphorylated at Ser161, unchanged; Figure 5) at the N-terminal end of the titin filaments calcineurin and alpha-actinin (Ser160, unchanged). Csrp3 localizes to the nucleus and does so in failing human heart in particular.\(^4\)\(^6\) Whether this is also phosphorylation dependent is currently unknown, although it is tempting to speculate that the AC3-I inhibited sites found here combined with increased CaMKII expression and activity in failing hearts are somehow connected. Illustrative of this is the immunolabeling of Csrp3, which colocalized with the GFP-tagged transgenic AC3-I at the sarcomere in our model system (Figure 5B).

The a-band is another location where strong effects of AC3-I were observed, suggesting a direct effect of CaMKII in the contractile response (Figure 5). In addition to myosin itself (Ser1368 in isoform-6, Q02566, 2-fold downregulated), several of its master regulators were also affected. Interesting were the observations on 2 isoforms of the myosin regulatory light chain, types 2 and 7 (Myl2 and Myl7). The former is the ventricular isoform, which had an intricate phosphorylation pattern concerning Ser14, Ser15, and Ser19;
Cardiac Phosphorylation Targets of CaMKII

Scholten et al

Figure 6. Compartment-specific regulation of myosin regulatory light chain. Alignment of the N-termini of Myl2 (1 to 52, ventricle) and Myl7 (1 to 60, atrium) reveals conservation of the 3 observed phosphorylation sites (yellow P and boldface) at Ser14, Ser15, and Ser19 in Myl2 and Ser22, Ser23 and Ser27 in Myl7. When comparing the quantitative data, we observed opposite regulation in both compartments as well as different consensus motifs for putative kinases at this site, suggesting that different kinases regulate these proteins in ventricles and atria. Arg20 of Myl7 (red R) is a putative CaMKII site, of which the phosphorylated form was found downregulated 2.5-fold. This arginine, and thus consensus site, is conserved for putative kinases at this site, suggesting that different kinases regulate these proteins in ventricles and atria. Arg20 of Myl7 (red R) is a putative CaMKII site, of which the phosphorylated form was found downregulated 2.5-fold. This arginine, and thus consensus site, is

Conclusions

The study described here is the first of its kind and highlights the feasibility of performing kinase-specific quantitative phosphoproteomics directly in cardiac mouse tissue. Using the transgenic model allowed us to isolate a small subset of 39 CaMKII-regulated phosphoproteins, including exact site localization, which provides a valuable resource for future research into CaMKII’s role in the healthy but also the diseased heart.

Acknowledgments

Salvatore Cappadona and Jeffrey R. Erickson are kindly acknowledged for bioinformatics support and initial experiments, respectively.

Sources of Funding

We acknowledge the financial support of the Fondation Leducq: the Alliance for CaMKII Signaling in Heart Disease (to Drs Scholten, Preisinger, Bourgonje, van Veen, Vos, Anderson, and Heck) and the Netherlands Proteomics Centre (to Drs Scholten, Preisinger, Corradini, Henrich, and Heck), embedded in the Netherlands Genomics Initiative, the NIH (R01HL70250, R01HL799031, R01HL113001, and R01HL096652) (to Dr Anderson), and Utrecht University’s Focus & Massa program (to Drs Scholten and van Veen).

Disclosures

None.
References

1. Löhse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93:896–910.

2. Latos MG, Karczewski P, Bartel S, Krause EG. The endogenous cardiac sarcoplasmic reticulum Ca$^{2+}$/CaM-dependent kinase is activated in response to beta-adrenergic stimulation and becomes Ca$^{2+}$-independent in intact beating hearts. J Biol Chem. 1997;272:13621–13626.

3. Rellos P, Pike AC, Niesen FH, Salah E, Lee WH, von Delft F, Knop S. Structure of the CaM binding domain of CaMKII complex reveals the molecular mechanism of CaMKII activation. PLoS Biol. 2010;8:e1000426.

4. Aye TT, Scholten A, Taouatas N, Varro A, Veen TA, Vos MA, Heck AJ. Proteome-wide protein concentrations in the human heart. Mol Biosyst. 2010;6:1917–1927.

5. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, Maier LS, Bers DM. Transgenic expression of delta-isoforms of the multifunctional Ca$^{2+}$/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ Res. 2003;93:896–910.

6. Cara-Bravo N, Morillo CA, Krum B, Regoli D, Despatie Y, Mahoney MJ. Role of the sarcoplasmic reticulum Ca$^{2+}$-release channel for diastolic function and arrhythmias in heart failure. Circulation. 2006;114:1352–1359.

7. Bourgonje VJ, Schoenmakers M, Beekman JD, van der Nagel R, Houtman MJ, Miedema LF, Antoon G, Spido K, de Windt LJ, Veen TA, Vos MA. Relevance of calcium/MuCal activation for arrhythmogenesis in the AV block dog. Heart Rhythm. 2010;7:1875–1883.

8. Hutterli EA, Jedrychowski P, Elias JE, Gossawmi T, Rad R, Beausoleil SA, Villen JJ, Haas W, Sower ME, Gygi SP. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell. 2010;143:1174–1189.

9. Zhou H, Low TY, Henrich ML, van der Toorn H, Schwend T, Zou H, Mohammed S, Heck AJ. Enhancing the identification of phosphopeptides from putative basophilic kinase substrates using Ti (IV) based IMAC enrichment. Mol Cell Proteomics. 2010;9:1187–1199.

10. Rubinsky B, Eisenberg S, Lakins J, Hoffman MR, Kellenberger C, Krum B. Identification of phosphopeptides and phospho-protein candidates in the failing heart. J Proteome Res. 2010;9:448–494.

11. Henrich ML, van den Toorn HW, Groenewold V, Heck AJ, Mohammed S. Ultra acidic strong cation exchange enabling the efficient enrichment of basic phosphopeptides. Anal Chem. 2012;84:1804–1808.

12. Attelaar AF, Frese CK, Preisinger C, Henrich ML, Schram AW, Timmers HT, Heck AJ, Mohammed S. Benchmarking stable isotope labeling based quantitative proteomics. J Proteomics. 2013;84:14–26.

13. Taus T, Kocher T, Pichler P, Paschke C, Schmidt A, Henrich C, Mechtler K. Universal and confident phosphoprotein site localization using phosphos. J Proteome Res. 2011;10:5354–5362.

14. Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K. Improved visualization of protein consensus sequences by iceLogo. Nat Methods. 2009;6:786–787.

15. van Veen TA, van Rijen HV, Oosterhuis RF, Opthof T, Colbert MC, Clement S, de Bakker JM, Jongsma H. Remodeling of gap junctions in mouse hearts hypertrophied by forced retinoic acid signaling. J Mol Cell Cardiol. 2002;34:1411–1423.

16. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Villen JJ, Li J, Cohn MA, Cantley LC, Gygi SP. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci USA. 2004;101:12130–12135.

17. Wu Y, Shintani A, Grueter CE, Zhang R, Hou Y, Yang J, Kranias EG, Colbran RJ, Anderson ME. Suppression of dynamic Ca$^{2+}$ transient responses to pacing in ventricular myocytes from mice with genetic calmodulin kinase II inhibition. J Mol Cell Cardiol. 2006;40:213–223.

18. Wu Y, Gao Z, Chen B, Koval OM, Singh MV, Guan X, Hund TJ, Kutschke W, Sarma S, Grumbach IM, Wehrens XH, Mohler PJ, Song LS, Anderson ME. Calmodulin kinase II is required for flight or flight sinoaoidal node physiology. Proc Natl Acad Sci USA. 2009;106:5972–5977.

19. Grueter CE, Abiria SA, Dzhura I, Masaoka T, Nishi M, Ryo A, Endo Y, Sawasaki T. The wheat germ cell-free system is a powerful tool for the understanding of phosphoprotein kinases and phosphatases. Proc Natl Acad Sci USA. 2006;53:641–645.

20. Schwamhannigan PD, Anderson ME. Calmodulin inhibition: breaking the cycle of electrical storm? Circulation. 2011;123:218–218.

21. Anderson ME, Brown JH, Bers DM. Calmodulin kinase activity in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468–473.

22. Anderson ME, Braun AP, Wu Y, Lu T, Schulman H, Stryjewski K, KN-93, an inhibitor of multifunctional Ca$^{2+}$/CaM-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. Am J Physiol. 1998;274:H1603–H1633.

23. Rivard D, Leblanc D, Dubois J, Meier S, Racine B, Dupuis L, Mercier C, Frechette F, Leblanc P. Identification of CaMKII autophosphorylation sites in the human heart. J Mol Cell Cardiol. 2003;36(7):2347–2354.
protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res. 2013;112:664–674.

44. Hidalgo CG, Chung CS, Saripalli C, Methawasin M, Hutchinson KR, Tsapralis G, Labeit S, Mattiazzi A, Granzier HL. The multifunctional Ca(2+)-calmodulin-dependent protein kinase II delta (CaMKIIdelta) phosphorylates cardiac titin’s spring elements. J Mol Cell Cardiol. 2013;54:90–97.

45. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88:393–403.

46. Boateng SY, Senyo SE, Qi L, Goldspink PH, Russell B. Myocyte remodeling in response to hypertrophic stimuli requires nucleocytoplasmic shuttling of muscle LIM protein. J Mol Cell Cardiol. 2009;47:426–435.

47. Kimura A. Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J Hum Genet. 2010;55:81–90.

48. Tsukada T, Pappas CT, Moroz N, Antin PB, Kostyukova AS, Gregorio CC. Leiomodin-2 is an antagonist of tropomodulin-1 at the pointed end of the thin filaments in cardiac muscle. J Cell Sci. 2010;123:3136–3145.